JP2021504404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504404A5 JP2021504404A5 JP2020529368A JP2020529368A JP2021504404A5 JP 2021504404 A5 JP2021504404 A5 JP 2021504404A5 JP 2020529368 A JP2020529368 A JP 2020529368A JP 2020529368 A JP2020529368 A JP 2020529368A JP 2021504404 A5 JP2021504404 A5 JP 2021504404A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- ildr2
- ildr2 antibody
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 101001010614 Homo sapiens Immunoglobulin-like domain-containing receptor 2 Proteins 0.000 claims 2
- 102100030712 Immunoglobulin-like domain-containing receptor 2 Human genes 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 1
- 101100072427 Homo sapiens ILDR2 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229940123751 PD-L1 antagonist Drugs 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592913P | 2017-11-30 | 2017-11-30 | |
| US62/592,913 | 2017-11-30 | ||
| PCT/EP2018/082779 WO2019105972A1 (en) | 2017-11-30 | 2018-11-28 | Ildr2 antagonists and combinations thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504404A JP2021504404A (ja) | 2021-02-15 |
| JP2021504404A5 true JP2021504404A5 (enExample) | 2022-01-06 |
| JP7350740B2 JP7350740B2 (ja) | 2023-09-26 |
Family
ID=64559680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529368A Active JP7350740B2 (ja) | 2017-11-30 | 2018-11-28 | Ｉｌｄｒ２アンタゴニストおよびその組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11655297B2 (enExample) |
| EP (1) | EP3717007B1 (enExample) |
| JP (1) | JP7350740B2 (enExample) |
| KR (1) | KR20200096223A (enExample) |
| CN (1) | CN111655287B (enExample) |
| AR (1) | AR113850A1 (enExample) |
| AU (1) | AU2018376231A1 (enExample) |
| BR (1) | BR112020010767A2 (enExample) |
| CA (1) | CA3083675A1 (enExample) |
| IL (1) | IL274751B2 (enExample) |
| MX (1) | MX2020005483A (enExample) |
| PE (1) | PE20200956A1 (enExample) |
| RU (1) | RU2020121533A (enExample) |
| SG (1) | SG11202003323TA (enExample) |
| TW (1) | TW201934119A (enExample) |
| WO (1) | WO2019105972A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3136510A1 (en) * | 2019-04-11 | 2020-10-15 | Bayer Aktiengesellschaft | Combinations of anti-ildr2 antibodies and pd-1 antagonists |
| CN111558038B (zh) * | 2020-05-27 | 2022-04-19 | 北京加美康联健康管理集团有限公司 | 一种用于癌症治疗的免疫检查点抑制剂 |
| CN111574626B (zh) * | 2020-05-27 | 2021-12-31 | 斯爱玲 | 一种ildr2抗体、其药物组合物及其用途 |
| US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
| US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
| WO2022072718A1 (en) | 2020-09-30 | 2022-04-07 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| ES2719728T3 (es) * | 2007-09-04 | 2019-07-12 | Compugen Ltd | Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos |
| AU2011272941B2 (en) * | 2010-06-30 | 2014-05-29 | Compugen Ltd. | C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| CA2836855C (en) * | 2011-06-30 | 2020-07-14 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| US20170233473A1 (en) * | 2014-05-27 | 2017-08-17 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
| EP2756093A4 (en) * | 2012-02-01 | 2015-07-01 | Compugen Ltd | C10RF32 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER |
| US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| KR102186027B1 (ko) | 2014-04-10 | 2020-12-03 | 다이이치 산쿄 유럽 게엠베하 | 항her3 항체-약물 콘주게이트 |
| CA2998350A1 (en) | 2015-09-16 | 2017-03-23 | John Lippincott | Anti-cd115 antibodies |
-
2018
- 2018-11-28 SG SG11202003323TA patent/SG11202003323TA/en unknown
- 2018-11-28 RU RU2020121533A patent/RU2020121533A/ru unknown
- 2018-11-28 MX MX2020005483A patent/MX2020005483A/es unknown
- 2018-11-28 CN CN201880077055.9A patent/CN111655287B/zh active Active
- 2018-11-28 IL IL274751A patent/IL274751B2/en unknown
- 2018-11-28 EP EP18811506.7A patent/EP3717007B1/en active Active
- 2018-11-28 BR BR112020010767-0A patent/BR112020010767A2/pt not_active IP Right Cessation
- 2018-11-28 AU AU2018376231A patent/AU2018376231A1/en not_active Abandoned
- 2018-11-28 US US16/766,224 patent/US11655297B2/en active Active
- 2018-11-28 CA CA3083675A patent/CA3083675A1/en active Pending
- 2018-11-28 WO PCT/EP2018/082779 patent/WO2019105972A1/en not_active Ceased
- 2018-11-28 KR KR1020207015214A patent/KR20200096223A/ko not_active Ceased
- 2018-11-28 PE PE2020000620A patent/PE20200956A1/es unknown
- 2018-11-28 JP JP2020529368A patent/JP7350740B2/ja active Active
- 2018-11-28 AR ARP180103490A patent/AR113850A1/es not_active Application Discontinuation
- 2018-11-30 TW TW107142979A patent/TW201934119A/zh unknown